Showing 2341-2350 of 3223 results for "".
- Allergan to Present Data from its Eye Care Portfolio at the AAO Annual Meeting, Including New Vuity Analysishttps://modernod.com/news/allergan-to-present-data-from-its-eye-care-portfolio-at-the-aao-annual-meeting-including-new-vuity-analysis/2480415/
- FDA Approves Allergan's Vuity, the First and Only Eye Drop to Treat Presbyopiahttps://modernod.com/news/fda-approves-allergans-vuity-the-first-and-only-eye-drop-to-treat-presbyopia/2480385/
- J&J Vision Announces New Collaboration Aimed at Eliminating Inequities in the Eye Care Industryhttps://modernod.com/news/johnson-johnson-vision-announces-new-collaboration-aimed-at-eliminating-inequities-in-the-eye-care-industry/2480280/Johnson & Johnson Vision announced a collaboration with
- Modernizing Medicine Showcases Single-Screen Innovations at ASCRShttps://modernod.com/news/modernizing-medicine-showcases-single-screen-innovations-at-ascrs/2479405/Modernizing Medicine announced it has enhanced its electronic health records (EHR), EMA with functionality that can help to speed up documentation by removing steps in note-taking and allowing for quick editing, importing charts and more. These new and improved workflows for clinical docu
- Hi-Health Announces Elevated Quality Process for Vista Advanced Supplementshttps://modernod.com/news/hi-health-announces-elevated-quality-process-for-vista-advanced-supplements/2479392/Hi-Health’s eye care brand, Vista OTC, is manufactured in cGMP certified and FDA regulated facilities. Hi-Health released a news release providing additional information about its quality standar
- New Contact Lens Update Focuses on Ocular Allergyhttps://modernod.com/news/new-contact-lens-update-focuses-on-ocular-allergy/2479141/The Centre for Ocular Research & Education (CORE) has published issue number 59 of its free online education magazine,
- Amydis Completes Pre-IND Meeting With the FDA for the Development of a Retinal Tracer for the Diagnosis of Alpha-Synucleinopathieshttps://modernod.com/news/amydis-completes-pre-ind-meeting-with-the-fda-for-the-development-of-a-retinal-tracer-for-the-diagnosis-of-alpha-synucleinopathies/2479113/Amydis announced completion of pre-Investigational New Drug (IND) interaction with the FDA regarding the current development plan for a small-molecule retinal tracer for the diagnosis of α-synucleinopathies (ASYN). Funding provided by The Michael J. Fox Foundation for Parkinson’s
- Bayer Strikes Alliance to Advance CureVac’s COVID-19 Vaccine CVnCoVhttps://modernod.com/news/bayer-strikes-alliance-to-advance-curevacs-covid-19-vaccine-cvncov/2478735/Bayer said that it has reached an agreement to further the development, supply and key territory operations of CureVac’s COVID-19 vaccine candidate CVnCoV. The companies indicated that they plan to combine their strengths for CureVac to be in a position to supply “hundreds of millions
- FDA Approves Eyenovia’s IND Application for MicroLine for Presbyopia, Allowing for Phase 3 Trialshttps://modernod.com/news/fda-approves-eyenovias-ind-application-for-microline-for-presbyopia-allowing-for-phase-3-trials/2478620/Eyenovia announced that the FDA has accepted its investigational new drug (IND) application for MicroLine, a proprietary pilocarpine formulation for the improvement in near vision in patients with presbyopia. The company intends to initiate the phase 3 VISION program, beginning with the VISION-1
- Data Confirm Immune Response From AstraZeneca’s COVID-19 Vaccine in Elderlyhttps://modernod.com/news/data-confirm-immune-response-from-astrazenecas-covid-19-vaccine-in-elderly/2478582/Study results published in The Lancet suggest that the chimpanzee adenovirus-vectored COVID-19 vaccine being developed by AstraZeneca and the University of Oxford is able to produce a strong immune response in older adults, whilst being better tolerated in this age group than compared wi